Ipswich Investment Management Co. Inc. Reduces Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Ipswich Investment Management Co. Inc. reduced its stake in Thermo Fisher Scientific Inc. by 32.2%, holding 4,370 shares valued at $1.77 million after the sale.
• In contrast, Eagle Global Advisors LLC increased its holdings by 69.2%, bringing its total to 36,369 shares worth approximately $14.75 million.
• Thermo Fisher Scientific's recent earnings report showed a net margin of 15.24% and earnings per share of $5.36, exceeding expectations and reflecting a 2.9% revenue increase year-over-year.

Ipswich Investment Management Co. Inc. lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 32.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,370 shares of the medical research company's stock after selling 2,075 shares during the quarter. Ipswich Investment Management Co. Inc.'s holdings in Thermo Fisher Scientific were worth $1,772,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. Eagle Global Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 69.2% in the second quarter. Eagle Global Advisors LLC now owns 36,369 shares of the medical research company's stock valued at $14,746,000 after purchasing an additional 14,870 shares during the period. Cove Private Wealth LLC boosted its stake in Thermo Fisher Scientific by 8.4% during the second quarter. Cove Private Wealth LLC now owns 3,886 shares of the medical research company's stock worth $1,576,000 after buying an additional 300 shares during the period. Patton Fund Management Inc. purchased a new position in Thermo Fisher Scientific during the second quarter worth about $210,000. Destiny Wealth Partners LLC purchased a new position in Thermo Fisher Scientific during the second quarter worth about $207,000. Finally, BOS Asset Management LLC purchased a new position in Thermo Fisher Scientific during the second quarter worth about $222,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Up 1.1%

Shares of NYSE:TMO opened at $464.18 on Friday. The firm's 50 day moving average price is $476.70 and its 200 day moving average price is $448.02. The stock has a market cap of $175.28 billion, a price-to-earnings ratio of 26.85, a price-to-earnings-growth ratio of 2.49 and a beta of 0.75. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $623.77. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm's revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the company earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 400 shares of the firm's stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. The trade was a 0.35% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock valued at $14,182,963 over the last 90 days. 0.33% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

TMO has been the subject of several research analyst reports. Barclays raised shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $490.00 to $550.00 in a research note on Thursday, September 11th. Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the stock an "outperform" rating in a research note on Tuesday, September 2nd. Wells Fargo & Company lowered their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research note on Thursday, July 24th. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Finally, HSBC reissued a "hold" rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat, Thermo Fisher Scientific has an average rating of "Moderate Buy" and an average price target of $588.35.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.